When cervical cancer returns after initial treatment, patients and their doctors face a challenging situation that requires careful planning and a tailored approach to care. The choices available depend on where the cancer has come back, what treatments were used before, and the patient’s overall health and wishes.

Understanding Treatment Goals and Options

Recurrent cervical cancer means the disease has come back after being treated. This can happen in the cervix itself, nearby organs in the pelvis such as the uterus, or in more distant parts of the body. The location and extent of the recurrence plays a major role in deciding what treatment path to take.^[1]

Treatment for recurrent cervical cancer has several possible goals. For some patients, especially those with cancer that has returned only in a small, localized area, the goal may be to eliminate the cancer entirely. For others, particularly when the cancer has spread to multiple sites or distant organs, the focus shifts to controlling symptoms, slowing the progression of disease, and maintaining quality of life for as long as possible.^[8]

What was done during the first round of treatment matters greatly. If a patient had surgery alone without radiation, they might still be able to receive radiation therapy. But if radiation was already given to the pelvis, delivering more radiation to the same area becomes much more complicated and risky. This is why doctors carefully review the entire treatment history before recommending the next steps.^[1]

Standard treatments exist that have been tested and approved by medical organizations and cancer societies. At the same time, researchers around the world are studying new drugs and innovative approaches in clinical trials—carefully designed studies that test whether new treatments are safe and effective. Some patients may be candidates for these trials, which can offer access to promising therapies not yet widely available.^[4]

Standard Treatment Approaches

Radiation Therapy Combined with Chemotherapy

For patients who had surgery as their initial treatment and did not receive radiation, chemoradiation—the combination of radiation therapy and chemotherapy given at the same time—is often the preferred treatment when cancer returns in the pelvis. The chemotherapy, usually based on a drug called cisplatin, makes the cancer cells more sensitive to radiation, helping the radiation work more effectively.^[1]

The chemotherapy drugs most commonly used alongside radiation include 5-fluorouracil (also called 5-FU) combined with cisplatin, or mitomycin with cisplatin. These drugs are given through a vein during the same period when radiation treatments are happening. The goal is to increase the chances of destroying the cancer while limiting damage to surrounding healthy tissue.^[3]

However, delivering high doses of radiation safely becomes much more difficult if a patient has already received radiation to the pelvis during their first treatment. The tissues in that area have already been exposed, and giving more radiation carries a higher risk of serious side effects such as damage to the bladder, rectum, or intestines. In these cases, doctors must be extremely careful and may use different techniques or lower doses.^[8]

Radiation therapy can also be used with a palliative goal—meaning it is given not to cure the cancer, but to relieve symptoms such as pain, bleeding, or pressure on nearby organs. Even when a cure is not possible, radiation can significantly improve comfort and quality of life.^[3]

Surgical Options for Central Pelvic Recurrence

For women who have already received radiation therapy and develop a recurrence limited to the central part of the pelvis, surgery may offer the only chance for a potential cure. The operation, called pelvic exenteration, is extensive and complex. It involves removing not just the cervix and uterus, but also other pelvic organs depending on where the cancer has spread—this can include the bladder, rectum, part of the colon, and the vagina.^[1]

Pelvic exenteration is only considered when imaging and other tests show that the cancer has not spread outside the pelvis and when surgeons believe they can remove all visible cancer with clear margins—meaning no cancer cells are left at the edges of what is removed. If cancer has spread to the side walls of the pelvis or to distant organs, this surgery is not performed because it would not be able to remove all the disease.^[3]

Outcomes after pelvic exenteration vary. In recent studies, the five-year survival rate for patients who underwent this surgery ranged from 21% to 61%. The operative mortality—the risk of dying during or shortly after the surgery—ranged from 1% to 10%. Patients tend to do better if the cancer is small, if lymph nodes do not contain cancer, if the surgical margins are free of cancer cells, and if a longer time has passed since the original diagnosis.^[8]

After such extensive surgery, reconstructive procedures are now strongly recommended. These can include creating a new way for urine to leave the body (called a continent urinary conduit), reconnecting parts of the colon to allow bowel function, and reconstructing the vagina using tissue flaps from other parts of the body. These reconstructive techniques help patients recover function and improve quality of life after the operation.^[1]

For patients with a small recurrence limited to the cervix or uterus who have not had prior radiation, a less extensive surgery called radical hysterectomy may be an option. This operation removes the uterus, cervix, surrounding tissues, and sometimes nearby lymph nodes, but does not require removal of the bladder or rectum.^[3]

Chemotherapy for Symptom Control

When recurrent cervical cancer has spread to distant parts of the body or cannot be treated with surgery or radiation, chemotherapy is given with the goal of controlling symptoms and slowing the cancer’s growth. This is called palliative chemotherapy—it is not expected to cure the cancer, but it can help patients feel better and live longer.^[1]

Cisplatin remains the most widely used single drug for recurrent cervical cancer. When used alone, it produces responses (meaning the cancer shrinks or stops growing) in about 17% to 38% of patients. The median overall survival for patients receiving single-agent cisplatin is approximately 6 to 7 months.^[8]

Combination chemotherapy—using two or more drugs together—tends to produce higher response rates than cisplatin alone, ranging from 22% to 68% in various studies. However, even with combinations, the median overall survival typically remains less than one year. Common two-drug combinations include:^[1]

• Cisplatin and ifosfamide
• Cisplatin and paclitaxel
• Cisplatin and gemcitabine
• Cisplatin and topotecan
• Paclitaxel and topotecan

Other chemotherapy drugs that may be used, either alone or in combination, include carboplatin, docetaxel, irinotecan, vinorelbine, epirubicin, and doxorubicin. The choice of drugs depends on what treatments the patient received before, how well their body can tolerate chemotherapy, and what side effects are acceptable.^[3]

An important study by the Gynecologic Oncology Group (GOG) found that the combination of topotecan plus cisplatin resulted in significantly longer survival compared to cisplatin alone in patients with metastatic, recurrent, or persistent cervical cancer. A follow-up study showed a trend toward longer survival and better quality of life for the combination of cisplatin plus paclitaxel when compared to other two-drug combinations such as cisplatin with topotecan, vinorelbine, or gemcitabine.^[8]

Side effects from chemotherapy vary depending on which drugs are used. Common side effects can include nausea, vomiting, fatigue, hair loss, increased risk of infection due to low white blood cell counts, anemia, and neuropathy (numbness or tingling in the hands and feet). Doctors work closely with patients to manage these side effects and adjust treatment as needed.^[3]

Targeted Therapy

Targeted therapy uses drugs that specifically attack cancer cells based on certain characteristics they possess, often causing less harm to normal cells than traditional chemotherapy. For recurrent cervical cancer, the most commonly used targeted therapy drug is bevacizumab (brand name Avastin).^[3]

Bevacizumab works by blocking the formation of new blood vessels that tumors need to grow—a process called angiogenesis. By cutting off the tumor’s blood supply, the drug can help slow its growth. Bevacizumab is typically given in combination with chemotherapy rather than alone. It is administered through a vein, usually every two or three weeks.^[9]

Immunotherapy

Immunotherapy represents a newer approach that helps the body’s own immune system recognize and fight cancer cells. The immune system normally protects us from infections and abnormal cells, but cancer cells can sometimes hide from immune detection. Immunotherapy drugs work to remove these hiding mechanisms and strengthen the immune response against cancer.^[3]

Two immunotherapy drugs are used for recurrent cervical cancer: pembrolizumab (Keytruda) and cemiplimab (Libtayo). Pembrolizumab can be given in combination with chemotherapy and sometimes also with bevacizumab. It is only used for tumors that have a specific protein called PD-L1 on their surface, which must be confirmed through testing.^[9]

Cemiplimab is typically offered when chemotherapy has been tried but did not work, or when the cancer comes back after chemotherapy. Like pembrolizumab, it works by blocking checkpoint proteins that prevent the immune system from attacking cancer cells.^[3]

Treatment in Clinical Trials

Clinical trials offer patients access to cutting-edge treatments that are still being studied. These trials are carefully designed research studies that test whether new drugs, combinations of treatments, or innovative approaches are safe and effective. Participation in a clinical trial may be an option for patients who have exhausted standard treatments or who want to contribute to advancing medical knowledge.^[4]

Clinical trials proceed through phases. Phase I trials primarily focus on safety—researchers want to know if a new treatment is safe to give to humans, what dose should be used, and what side effects occur. These trials usually involve a small number of patients. Phase II trials evaluate whether the treatment actually works against the cancer—does it make tumors shrink or stop growing? These trials involve more patients. Phase III trials compare the new treatment to the current standard treatment to see if the new approach is better, equally effective, or has fewer side effects. These are large studies involving hundreds or even thousands of patients.^[4]

Molecularly Targeted Therapies Under Investigation

Beyond bevacizumab, which is already approved, researchers are studying other molecularly targeted therapies for recurrent cervical cancer. These investigational treatments are designed to interfere with specific molecules and pathways that cancer cells use to grow and survive. While still experimental, they represent promising avenues for future treatment.^[8]

Some experimental targeted therapies focus on blocking growth factor receptors on cancer cells. Growth factors are proteins that tell cells to divide and grow. By blocking the receptors that receive these signals, the drugs can slow or stop cancer growth. Other approaches target enzymes that cancer cells need to repair their DNA or to invade surrounding tissues.^[1]

These molecularly targeted agents are being tested both alone and in combination with standard chemotherapy. The idea behind combining them with chemotherapy is that they might work together synergistically—each attacking the cancer through different mechanisms, potentially producing better results than either approach alone.^[8]

Combination Approaches and Novel Strategies

Researchers are also exploring whether combining immunotherapy with other treatments can improve outcomes. Studies are testing immunotherapy drugs together with chemotherapy, with targeted therapy like bevacizumab, or even with radiation therapy. The rationale is that chemotherapy and radiation might make cancer cells more visible to the immune system, while immunotherapy helps the immune system attack more effectively.^[9]

Clinical trials for recurrent cervical cancer are conducted at cancer centers around the world, including in Europe, the United States, and other regions. Eligibility for these trials depends on many factors, including the patient’s prior treatments, the extent and location of the cancer, overall health status, and specific characteristics of the tumor such as whether it has certain genetic markers or protein expressions.^[4]

Patients interested in clinical trials should discuss this option with their oncology team. Doctors can search for appropriate trials based on the patient’s specific situation and explain the potential benefits and risks. Participating in a trial may provide access to promising new treatments before they become widely available, and it contributes valuable information that can help future patients.^[4]

Most common treatment methods

• Chemoradiation
  • Combination of radiation therapy and chemotherapy given at the same time, most often for patients with pelvic recurrence who did not previously receive radiation
  • Cisplatin-based chemotherapy makes radiation more effective
  • May include 5-fluorouracil plus cisplatin, or mitomycin plus cisplatin
  • Can be the preferred treatment for isolated para-aortic lymph node recurrence
• Surgery
  • Pelvic exenteration for central pelvic recurrence in patients who previously received radiation
  • Involves removal of multiple pelvic organs including potentially the bladder, rectum, and vagina
  • Five-year survival rates range from 21% to 61% depending on factors like tumor size and lymph node status
  • Pelvic reconstructive procedures strongly recommended after exenteration
  • Radical hysterectomy may be option for small, localized recurrence in patients without prior radiation
• Chemotherapy
  • Cisplatin is the most widely used single agent with response rates of 17-38%
  • Combination regimens achieve higher response rates of 22-68%
  • Common combinations include cisplatin with paclitaxel, gemcitabine, topotecan, or ifosfamide
  • Carboplatin, docetaxel, irinotecan, vinorelbine, epirubicin, and doxorubicin are also used
  • Median overall survival typically less than one year with palliative chemotherapy
• Targeted Therapy
  • Bevacizumab (Avastin) is the most common targeted therapy drug
  • Works by blocking new blood vessel formation that tumors need to grow
  • Usually given in combination with chemotherapy
  • Other molecularly targeted therapies are under investigation in clinical trials
• Immunotherapy
  • Pembrolizumab (Keytruda) may be given with chemotherapy and sometimes bevacizumab
  • Only used for tumors with PD-L1 checkpoint protein
  • Cemiplimab (Libtayo) offered when chemotherapy did not work or cancer returned after chemotherapy
  • Works by strengthening immune system’s ability to recognize and fight cancer
• Radiation Therapy
  • External beam radiation, brachytherapy, or both
  • Often combined with chemotherapy but may be used alone in some cases
  • Used for palliative purposes to relieve pain, stop bleeding, or control symptoms
  • More difficult to deliver safely if patient previously received pelvic radiation